Effects of intra-articular botulinum toxin type A in an equine model of acute synovitis: A pilot study

American Journal of Physical Medicine and Rehabilitation

Volumn 86, Issue 10, 2007, Pages 777-783

  DePuy, Tracy ^a   Howard, Rick ^a   Keegan, Kevin ^a   Wilson, David ^a   Kramer, Joanne ^a   Cook, James L ^a   Childers, Martin K ^b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Animal Study; Arthritis; Botulinum Toxin; Inflammation; Joint; Pain

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; RECOMBINANT INTERLEUKIN 1BETA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL LAMENESS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARPAL BONE; CONTROLLED STUDY; CYTOLOGY; GAIT; HISTOPATHOLOGY; HORSE; KINEMATICS; NONHUMAN; RANDOMIZATION; RECOMMENDED DRUG DOSE; SYNOVIAL FLUID; SYNOVITIS;

ACUTE DISEASE; ANIMALS; BOTULINUM TOXIN TYPE A; GAIT; HORSES; INJECTIONS, INTRA-ARTICULAR; NEUROMUSCULAR AGENTS; OSTEOARTHRITIS; PILOT PROJECTS; RANDOM ALLOCATION; SYNOVIAL FLUID; SYNOVITIS;

EID: 34748926971     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/PHM.0b013e3181157718     Document Type: Article

References (44)

1. Jankovic J: Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7
2. Mahowald ML, Singh JA, Dykstra D: Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res 2006;9:179-88
3. Jankovic J: Treatment of dystonia. Lancet Neurol 2006;5:864-72
4. Comella CL, Thompson PD: Treatment of cervical dystonia with botulinum toxins. Eur J Neurol 2006;13(suppl 1):16-20
5. Brashear A: The safety and tolerability of botulinum toxins for the treatment of cervical dystonia. Expert Opin Drug Saf 2005;4:241-9
6. Samton J, Mauskop A: Treatment of headaches with botulinum toxin. Expert Rev Neurother 2006;6:313-22
7. Mathew NT: Tension-type headache. Curr Neurol Neurosci Rep 2006;6:100-5
8. Nissan GR, Diamond ML: Advances in migraine treatment. J Am Osteopath Assoc 2005;105(4 suppl 2):9S-15S
9. Nelson R: Non surgical therapy for anal fissure. Cochrane Database Syst Rev 2006;(4):CD003431
10. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK: Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002;81:751-9
11. Bistritz L, Bain VG: Sphincter of Oddi dysfunction: managing the patient with chronic biliary pain. World J Gastroenterol 2006;12:3793-802
12. Toft BR, Nordling J: Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol 2006;16:268-72
13. Moore C, Rackley R, Goldman H: Urologic applications of botox. Curr Urol Rep 2005;6:419-23
14. Chikhani L, Dichamp J: Bruxism, temporo-mandibular dysfunction and botulinum toxin [in French]. Ann Readapt Med Phys 2003;46:333-7
15. Aoki KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(suppl 1):S9-15
16. Aoki KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93
17. Mense S: Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004;251(suppl 1):I1-7
18. Mahant N, Clouston PD, Lorentz IT: The current use of botulinum toxin. J Clin Neurosci 2000;7:389-94
19. Comella CL, Jankovic J, Brin MF: Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 2000;55(12 suppl 5):S15-21
20. Lu CS, Chen RS, Tsai CH: Double-blind, placebo-controlled study of botulinum toxin injections in the treatment of cervical dystonia. J Formos Med Assoc 1995;94:189-92
21. Blumenfeld AM, Dodick DW, Silberstein SD: Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin 2004;22:167-75
22. Dodick DW: Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003;43(suppl 1):S25-33
23. Haldeman S, Dagenais S: Cervicogenic headaches: a critical review. Spine J 2001;1:31-46
24. Rubenstein EJ: Botulinum toxin for headache. Int Ophthalmol Clin 2005;45:93-7
25. Silberstein SD: Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2001;2:1649-54
26. Caron JP: Intra-articular injections for joint disease in horses. Vet Clin North Am Equine Pract 2005;21:559-73
27. Keegan KG, Pai PF, Wilson DA, Smith BK: Signal decomposition method of evaluating head movement to measure induced forelimb lameness in horses trotting on a treadmill. Equine Vet J 2001;33:446-51
28. Takafuji VA, McIlwraith CW, Howard RD: Effects of equine recombinant interleukin-1alpha and interleukin-1beta on proteoglycan metabolism and prostaglandin E2 synthesis in equine articular cartilage explants. Am J Vet Res 2002;63:551-8
29. Keegan KG, Arafat S, Skubic M, Wilson DA, Kramer J: Detection of lameness and determination of the affected forelimb in horses by use of continuous wavelet transformation and neural network classification of kinematic data. Am J Vet Res 2003;64:1376-81
30. Dyson S, Murray R: Pain associated with the sacroiliac joint region: a clinical study of 74 horses. Equine Vet J 2003;35:240-5
31. American Association of Equine Practitioners: AAEP Guide for Veterinary Service and Judging of Equestrian Events, ed 4. Lexington, KY, American Association of Equine Practitioners, 1991
32. Frisbie DD, Kawcak CE, Baxter GM, et al: Effects of 6alpha- methylprednisolone acetate on an equine osteochondral fragment exercise model. Am J Vet Res 1998;59:1619-28
33. Morris EA, McDonald BS, Webb AC, Rosenwasser LJ: Identification of interleukin-1 in equine osteoarthritic joint effusions. Am J Vet Res 1990;51:59-64
34. Moskowitz RW, Sunshine A, Hooper M, Olson NZ, Cawkwell GD: An analgesic model for assessment of acute pain response in osteoarthritis of the knee. Osteoarthritis Cartilage 2006;14:1111-8
35. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M: Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997;24:365-71
36. Frisbie DD, McIlwraith CW: Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clin Orthop Relat Res 2000;379(suppl):S273-87
37. Howard RD, McIlwraith CW, Trotter GW, Nyborg JK: Cloning of equine interleukin 1 alpha and equine interleukin 1 beta and determination of their full-length cDNA sequences. Am J Vet Res 1998;59:704-11
38. Resman-Targoff BH: Medical therapy: where are we now? Am J Health Syst Pharm 2006;63(18 suppl 4):S11-8
39. Sanghi S, MacLaughlin EJ, Jewell CW, et al: Cyclooxygenase-2 inhibitors: a painful lesson. Cardiovasc Hematol Disord Drug Targets 2006;6:85-100
40. Schaible HG, Schmelz M, Tegeder I: Pathophysiology and treatment of pain in joint disease. Adv Drug Deliv Rev 2006;58:323-42
41. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Mullner M: Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005;172:1039-43
42. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M: Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006;13(suppl 4):35-40
43. Turkel CC, Bowen B, Liu J, Brin MF: Pooled analysis of the safety of botulinum toxin type A in the treatment of post-stroke spasticity. Arch Phys Med Rehabil 2006;87:786-92
44. Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004;20:981-90